




SG
SIGHTGLASS
VISION

Powered by
Diffusion
Optics
Technology™

**Act early to help slow
myopia progression**

Introducing NEW SightGlass Vision™ spectacle lenses
powered by Diffusion Optics Technology™.

Myopia is rapidly increasing globally



In 2010, **28%** of the global population was myopic¹



By 2050, **50%** of the global population is predicted to be myopic¹

Children are becoming myopic at an **earlier age**¹

Presence of myopia increases the risk of future ocular complications²

Increased risk of developing myopia-related pathology (versus emmetrope)²



Glaucoma

1.7 X

Up to 3 dioptres of myopia



Retinal detachment

7.8 X

For any degree of myopia



Myopic maculopathy

18 X

For any degree of myopia

The increase in childhood myopia is associated with many factors linked to **modern lifestyles**³



More screen time




Less outside time




Greater educational demands

There is no safe level of myopia.² The risk to future eye health increases when axial length exceeds 26 mm




Early intervention may slow the progression of myopia in children^{5,6*}




*Loosely based on average progression data from Polling JR, et al. *Br J Ophthalmol* [Epub ahead of print] 2020. doi:10.1136/bjophthalmol-2020-316234. **Assumes a 50% treatment effect / reduction in myopia progression.

Introducing new SightGlass Vision powered by Diffusion Optics Technology™




SightGlass Vision spectacle lenses with Diffusion Optics Technology is a new and unique lens technology which reduces contrast to help slow axial elongation in myopia.⁹




*SightGlass Vision spectacle lenses slow axial length elongation and myopia progression in children while correcting refractive error. Reduction in progression of spherical equivalent refraction and axial length from baseline over 24 months was 47% and 24% on average, respectively (p<0.0041)

The efficacy and safety of Diffusion Optics Technology™ spectacle lenses in reducing progression of childhood myopia has been tested in CYPRESS, a randomized, controlled, double-masked, multi-site, parallel group clinical trial.¹² 256 children aged 6-10, many ethnicities.

59% reduction in myopia progression, on average, in children with full time wear over 2 years.^{12*}



And **4 in 10** children showed no clinically meaningful progression in refractive error^{12 ‡}



*Compared to control spectacle lenses over 24 months. Analysis based on parent responses to in-office question, "Does your child remove their spectacles for any near vision activities?" (n=51 test, n=62 control). For the full study cohort, reduction in progression of spherical equivalent refraction and axial length from baseline over 24 months was 47% and 24% on average respectively. ‡No clinically meaningful change in refractive error means that there was less than a 0.25D increase in myopia from baseline as measured by cycloplegic autorefraction (p<0.0001).

Diffusion Optics Technology™ spectacles are designed to fit seamlessly into your practice

Diffusion Optics Technology™ spectacle lenses are prescribed like many other single-vision spectacle lenses.¹²

No extra chair time
Pupil center height measurements required.

Easy to fit

Diffusion Optics Technology™ spectacle lenses were particularly effective in the youngest patients, aged 6–7 years old, who have the fastest progression, where no other spectacles have been evaluated for effectiveness.¹²

Children readily adapt to Diffusion Optics Technology™¹²




Wearing time

Average wearing time for both Diffusion Optics Technology™ and regular spectacles was **more than 12 hours each day over 2 years**^{12*}



93% of children loved their Diffusion Optics Technology™ glasses after one month of wear.



Acceptance



* SightGlass Vision spectacle lenses are indicated to be worn constantly for all activities except for those outlined in WARNINGS (a minimum of 10 hours per day). †Proportion agreeing to "I love my glasses" at the 30-day, 6-month, 12-month, 18-month, and 24-month visits. ‡Proportion agreeing to "My glasses make me look cool" at the 30-day, 6-month, 12-month, 18-month, and 24-month visits.



Learn more about SightGlass Vision

Visit sightglassvision.com



References

1. Holden BA, et al. *Ophthalmol.* 2016;123:1036–42;
2. Flitcroft DI. *Prog Retin Eye Res.* 2012;31:622–660;
3. Németh J, et al. *Eur J Ophthalmol.* 2021;31(3):853–883;
4. Tideman J, et al. *JAMA Ophthalmol.* 2016;134(12):1355–1363;
5. Chamberlain P, et al. *Clinical evaluation of a dual-focus myopia control 1 day soft contact lens: 6-year results (2020 American Academy of Optometry Annual Meeting)*;
6. Polling JR, et al. *Br J Ophthalmol.* 2021;0:1–5;
7. Rappon J, et al. Novel DOT Lenses from SightGlass Vision Show Great Promise to Fight Myopia. Review of Myopia Management. Available at: <http://reviewofmm.com/novel-dot-lenses-from-sightglass-vision-show-great-promise-to-fight-myopia/> [Accessed Sep 2021];
8. Rappon J, et al. *Invest Ophthalmol Vis Sci.* 2019;60(9):5845–5845;
9. Rappon J, et al. *Optom Vis Sci.* 2020;97:E-abstract 200036;
10. Morgan IG & Rose KA. *Clin Exp Optom.* 2019;102(1):3–17;
11. Greenwald SH, et al. *Transl Vis Sci Technol.* 2017;6(3);
12. SGV data on file 2021. Control of Myopia Using Peripheral Diffusion Lenses: Efficacy and Safety Study, 24-month results (n = 256, 14 North American sites).

© 2023 SightGlass Vision

SightGlass Vision DOT O.2 Trivex Spectacle Lenses
SightGlass Vision, 4970 El Camino Real, Ste 100, 94022
Los Altos, California, US



Powered by

Diffusion
Optics
Technology™